Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for treatment. "We are thrilled to have our first participant enrolled," said Chief Executive Officer Cheri ...

The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

HYDERABAD: Lavender, vanilla, chamomile, citrus, cranberry, and whatnot. Sitting pretty and colourful in little glass jars or ...

Itchy breasts and nipples can be an uncomfortable experience that disrupts daily life. While occasional itching may seem ...

Besides making decadent seasonal lattes, this holiday favorite contains oil can support scalp health and may mitigate hair ...